PHILADELPHIA, Feb. 28,
2024 /PRNewswire/ -- Carisma Therapeutics
Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a
clinical-stage biopharmaceutical company focused on discovering and
developing innovative immunotherapies, today announced that
Steven Kelly, President and Chief
Executive Officer, will participate in the TD Cowen 44th
Annual Health Care Conference on Wednesday,
March 6th at 2:50 pm
ET.
An audio webcast of the event will be available on the
Company's Investor Events section of the Investor
Relations webpage and will be archived for a limited time following
the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-td-cowens-44th-annual-health-care-conference-302073454.html
SOURCE Carisma Therapeutics Inc.